Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Inflammatory demyelinating neuropathies
Glenn Lopate,
Alan Pestronk
Institute of Clinical and Translational Sciences (ICTS)
Section of Neuromuscular Medicine
Hope Center for Neurological Disorders
Research output
:
Contribution to journal
›
Review article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inflammatory demyelinating neuropathies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Human Immune System
100%
Immune Globulin
100%
Demyelinating Neuropathy
100%
Corticosteroids
71%
Plasma Exchange
71%
Guillain-Barré Syndrome
28%
Therapy Goals
28%
Therapy Choice
28%
Venous Access
28%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
28%
Adverse Effects
14%
High Dose
14%
Initial Treatment
14%
Bulbar
14%
Disease Severity
14%
Safety Profile
14%
Illness
14%
Moderate to Severe
14%
Cardiac Disease
14%
Immunosuppressive Agents
14%
Age-related Risk
14%
Patient Response
14%
Hepatic Disease
14%
Intensive Care Unit
14%
Activities of Daily Living
14%
Every Other Day
14%
Drug Choice
14%
Severe Symptoms
14%
Multicenter Randomized Controlled Trial
14%
Supportive Care
14%
Functional Capacity
14%
Methylprednisolone
14%
Hemodynamic Instability
14%
Gait Disorders
14%
Enhanced Strength
14%
Treatment Costs
14%
Potential Drug Interactions
14%
Side Effect Profile
14%
Immunomodulatory Therapy
14%
Chronic Treatment
14%
Mild Symptoms
14%
Good Safety
14%
Sensory Loss
14%
Therapy Experiences
14%
Respiratory muscle Strength
14%
Controlled Comparison
14%
Autonomic Instability
14%
Second-line Agents
14%
Anti-GM1
14%
Anti-glycolipid Antibody
14%
Immune Plasma
14%
GQ1b
14%
Strength Abilities
14%
Medicine and Dentistry
Human Immunoglobulin
100%
Demyelinating Neuropathy
100%
Plasma Exchange
71%
Health Care Cost
28%
Contraindication
28%
Polyradiculoneuropathy
28%
Liver Disease
14%
Disease Severity
14%
Randomized Controlled Trial
14%
Hemodynamic
14%
Heart Disease
14%
Drug Megadose
14%
Intensive Care Unit
14%
Weakness
14%
Supportive Care
14%
Mouth
14%
Deterioration
14%
Side Effect
14%
Drug Interaction
14%
Activities of Daily Living
14%
Methylprednisolone
14%
Immunomodulating Agent
14%
Antiserum
14%
Gait Disorder
14%
Comparison Trial
14%
Diseases
14%
Adverse Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Human Immunoglobulin
100%
Demyelinating Neuropathy
100%
Syndrome
28%
Polyradiculoneuropathy
28%
Liver Disease
14%
Randomized Controlled Trial
14%
Side Effect
14%
Disease Severity
14%
Heart Disease
14%
Immunomodulating Agent
14%
Drug Interaction
14%
Antiserum
14%
Deterioration
14%
Weakness
14%
Methylprednisolone
14%
Gait Disorder
14%
Comparison Trial
14%
Diseases
14%